Trius Therapeutics (TSRX) - watch as the results for 2nd Phase 3 gets closer (antibiotic), expected in early 2013. 1st Phase 3 results were good. Company has over $90 mil in cash, no debt, and Roche is partner -
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.